MedTrace Logo

Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project

NCT01820637 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2019-03-22

Study results available
· View outcomes & findings →

Summary

To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

Conditions

  • Atherosclerosis of Native Arteries of the Extremities

Interventions

DEVICE

The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)

Drug-eluting SFA self-expanding stent

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Stefan Müller-Hülsbeck, Prof. · Ev. Luth. Diakonissenanstalt Flensburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-23
Primary Completion
2014-12-31
Completion
2017-02-20

Countries

  • Australia
  • Austria
  • Belgium
  • Germany
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820637 on ClinicalTrials.gov